Bulk Supply High Purity 99% Anti Ulcer Raw Powder Rebamipide CAS 90098-04-7

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Solid
• Purity: >99%
• Model NO.: 90098-04-7
• Other Name: CAS 90098-04-7
• CAS: 90098-04-7
• Sample: Available
• Delivery Time: Prompt Delivery
• Shipping Time: 12-15 Workdays
• Package Size: 100g/1kg/25kg
• Usage: Anti-Ulcer Drugs
• Transport Package: Bottle, Can, Drum, Plastic Container, Vacuum Packe
• Specification: powder
• Trademark: Senwayer
• Origin: Wuhan, China
• HS Code: 0000000000
• Production Capacity: 2000 Kilograms Per Month

Product Description

Bulk Supply High Purity 99% Anti Ulcer Raw Powder Rebamipide CAS 90098-04-7

Name: Rebamipide
English synonyms: (+-)-1,2-dihydro-alpha-((4-chlorobenzoyl)amino)-2-oxo-4-quinolinepropanoica
CAS Number: 90098-04-7
Molecular formula: C19H15ClN2O4
Molecular weight: 370.79
EINECS number:1308068-626-2

Melting point: 288-290°C dec.
Boiling point: 695.0±55.0°C (Predicted)
Density: 1.394±0.06g/cm3 (Predicted)
Storage conditions: Sealed in dry, Room Temperature
Solubility: DMSO: >5mg/mL
Form: powder
Acidity coefficient (pKa): 3.38±0.10(Predicted)
Color: white

(1) Prevention and treatment of gastric mucosal damage caused by NSAIDs Rebamipide has a significant reversal of the side effects such as decreased gastric mucosal prostaglandin production and increased mucosal permeability caused by NSAIDs. Moreover, studies have found that patients taking NSAIDs have high expression of HIF-1 in the epithelial gastric mucosa, indicating that the gastric mucosa is in a hypoxic-ischemic state; while patients taking rebamipide have significantly lower HIF-1, indicating that rebamipide is taking NSAIDs The gastric mucosa of the patient has a good protective effect. From this point of view, rebamipide may have a preventive and therapeutic effect on gastric mucosal damage caused by NSAIDs (especially non-selective NSAIDs) drugs.

(2) HP-related gastritis treatment Haruma et al. reported that in the clinical observation of 86 HP-positive patients, 53 patients taking Rebamipide significantly reduced the infiltration of gastric antrum and gastric corpus monocytes and mesitocytes , Gastric inflammation was significantly reduced compared with those who did not take the medicine, indicating that it has a good quality effect on HP-related gastritis.

(3) Other studies have reported that the body temperature of gastric cancer patients who took rebamipide before surgery was significantly lower than that of the control group, and the serum IL-6 content was also significantly lower than that of the control group, indicating that rebamipide has an effect on gastric cancer. Systemic inflammatory response syndrome after surgery has a certain improvement effect; Rebamipide may become a new treatment for ulcerative colitis; it may become a new and effective treatment for Meniere's disease.